Mobile website
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
PHA-LAK cells were prepared from PBMC of healthy "O"-blood type donor (Primed with PHA for 48 hours then cultured in the presence of rIL - 2), showing predominantly CD3 CD8 in phenotype. The expression level of IL - 2R of PHA - LAK was higher than that of conventional LAK (C - LAK, induced by rIL - 2 only), andon the proliferative ability, in vitro survival time and cytotoxicity PHA-LAK exhibited some advantages thanC-LAK. 60 cases of various solid tumor patients (renal cell carcinoma 24 cases, liver cancer, malignant lyrnphoma,colon carcinoma 5 cases each, lung cancer 12 cases and other miscellaneous cancer 9 cases) were treated with PHA - LAK in combination with rIL - 2 (TGP - 3, Takeda, Japan) . The results of phase I and Phase II clinical trials indicated that PHA - LAK/IL - 2 therapy was relatively safe (showing very mild or no side effect) and effective (especially against renal cell carcinoma, malignant lymphoma and liver cancer) . Thus PHA-LAK/IL-2 might provide a new therapeutic approach to cancer adoptive immunotherapy.
Keywords:
Project Supported:
Clc Number:
